brazilian pharmaceutical market 2014

23
©notice This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of vision- gain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each pur- chase and single copy is for personal use only. Brazilian Pharmaceutical Market 2014-2024

Upload: visiongain

Post on 07-May-2015

2.265 views

Category:

Business


1 download

DESCRIPTION

For more information on this report please contact [email protected] (+44 (0) 2075499976) or refer to our website http://www.visiongain.com/Report/1157/Brazilian-Pharmaceutical-Market-2014-2024

TRANSCRIPT

Page 1: Brazilian pharmaceutical market 2014

©noticeThis material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of vision-gain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each pur-chase and single copy is for personal use only.

Brazilian Pharmaceutical Market 2014-2024

Page 2: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents

1.1 Overview of Findings

1.2 Chapters in the Report

1.3 Research and Analysis Methods

2.1 Market to Continue Strong Performance to 2024

2.2 The Sixth-Largest Economy in the World in 2012

2.2.1 Population Size the Biggest Driver for the Market

2.2.2 Generics Segment Continues to Grow in Importance

2.2.3 CNS Remains the Largest Therapeutic Area in 2012

2.2.4 Three Domestic Companies in Top Six for 2012

2.3 Why the Brazilian Market Matters: Regional and Global Market Context

2.3.1 Brazil Represented 46% of the Latin American Market in 2012

2.3.2 Brazil as Part of the BRIC/’Pharmerging’ Markets in 2013

2.3.2 Brazil as Part of the BRIC/’Pharmerging’ Markets in 20132.5.6 Other Players in the

Market2.8.1 The Vaccines Market

3.1 ANVISA The Key Institutional Body

3.1.1 Other Important Agencies

3.2 Over 62% Supplement SUS with Private Healthcare

3.2.1 CMED Adjusts Prices Up for 2013

3.2.2 Reimbursement for RENAME Drugs via Farmácia Popular

3.2.3 Private Insurance Market Growing, but Costs for Insurers Rising

3.3 M&A-Led Consolidation Continues in Both Wholesale and Retail Sectors

3.3.1 Celesio-Owned Panpharma Still the Top Distributor

3.3.2 RaiaDrogasil, Brazil Pharma and Other Major Chains Hold 47% of Retail Sector

3.3.3 Marketing Spend in Brazil Approaches $5bn

1. Executive Summary

2. Overview of the Brazil Pharmaceutical Market, 2014-2024

3. Brazilian Healthcare: Commercial Overview, 2014-2024

Page 3: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents 3.4 A Nation of Contrasts: Healthcare Variations in the Brazilian Regions

3.4.1 Southeast: Over 40% of the National Population, But Over Half of Pharmaceutical Market

Revenues

3.4.2 Northeast: Shortest Life-Expectancies and Second-Highest Market Share

3.4.3 South: Smallest Region with Highest Per Capita GDP

3.4.4 MidWest: Landlocked Region with Lowest Population

3.4.5 North: Largest and Poorest Area Represents <5% of Market

4.1 How Much Ground Will Generics Gain by 2024?

4.2 Patented Pharmaceuticals: Still the Basis of the Brazil Market

4.2.1 PDPs and HTA: Government Attempts to Regulate Costs

4.2.2 The Battle for Biomanufacturing Capabilities

4.2.3 Can BioNovis and Orygen Build on Aché’s Biosimilar Advances?

4.2.4 At 55% More Expensive, Can Patented Products Hold Off the Generics Revolution?

4.2.5 Market Forecast for Prescription Pharmaceuticals, 2014-2024

4.3 Generic Pharmaceuticals: Rapid Expansion Since 2000

4.3.1 Pró-Genéricos Anticipate 45% Market Capture

4.3.2 The Issue of Non-Bioequivalent Drugs

4.3.3 Counterfeits: Believed At Least 7% of Brazil's Drug Supply Affected

4.3.4 Generics Opportunity Not Yet Fully Harnessed

4.3.5 Market Forecast for Generic Pharmaceuticals, 2014-2024

4.4 OTC Segment: Still Favoured by Brazilian Consumers

4.4.1 Coming Out From Behind the Counter

4.4.2 Advertising: ABIMIP Lobbies on DTC Restrictions

4.4.3 Vitamins and Minerals Purchased by ~15% of Brazilians

4.4.4 From Analgesics to Erectile Dysfunction Treatments, Consumer Health Treatments Remain

Prominent in the Market

4.4.5 Market Forecast for the OTC Segment, 2014-2024

4. Product Mix in the Brazilian Market, 2014-2024

Page 4: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents 4.4.5 Market Forecast for the OTC Segment, 2014-2024

5.1 Oncology to Overtake CNS Diseases by 2024

5.2 The Rise of Non-Communicable Diseases

5.3 CNS Conditions: Disease Burden Comparable to US

5.3.1 Domestic Companies Target OTC and Generic Pain Relief

5.3.2 Foreign Competition in the Analgesics Area

5.3.3 Prevalence of 10%+ Represents Major Opportunity in Antidepressant Space

5.3.4 CNS Conditions: A Therapeutic Area with Unique Relevance to Brazil

5.3.5 Market Forecast for CNS Therapeutic Area 2014-2024

5.4 Cardiovascular Diseases: Brazil’s Biggest Killer

5.4.1 Anti-hypertensives: One of the Nation’s Key Drugs

5.4.2 Decline of the Statins

5.4.3 Ache and Sanofi Among the Key Players in This Field

5.4.4 The Heart Disease Opportunity over the Next 10 Years

5.4.5 Market Forecast for Cardiovascular Therapeutic Area 2014-2024

5.5 Alimentary/Metabolic Diseases: Affecting More Than a Third of Brazilians

5.5.1 Lack of Diabetes Awareness Still an Issue

5.5.2 Biosimilar Insulins to Play an Important Role

5.5.3 EMS’ Generic Esomeprazole an Important Addition

5.5.4 Capturing the Alimentary/Metabolic Disease Opportunity

5.5.5 Market Forecast for Alimentary/Metabolic Therapeutic Area 2014-2024

5.6 Oncology: To Become the Biggest Therapeutic Area?

5.6.1 Breast Cancer Has the Highest Prevalence in Brazil

5.6.2 Biosimilars to Help Widen Medicine Access

5.6.3 Eurofarma, Cristalia and Libbs the Domestic Leaders

5.6.4 Will the Oncology Therapeutic Area Realise its Potential?

5.6.5 Market Forecast for Cancer Treatment 2014-2024

5.7 Infectious Diseases: Brazil Faces Unique Challenges

5.7.1 PPDs to Meet Vaccines Need

5. Therapeutic Areas in the Brazil Market, 2014-2024

Page 5: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents 5.7.2 Brazil Managing HIV Despite IP Concerns

5.7.3 Chagas Disease and Other Infectious Disease Concerns

5.7.4 Infectious Disease: The Past or the Future for Brazilian Pharma?

5.7.5 Market Forecast for Infectious Disease Treatment, 2014-2024

5.8 Other Therapeutic Areas

6.1 EMS Continues to Lead the Field with 8% Market Share

6.2 Purchase of Medley Means Multinationals Still Own Bulk of Market

6.2.1 Domestic Firms Control 70% of Generics Market

6.3 EMS Pharma: First Among Brazilian Generics Firms

6.3.1 Significant R&D, Manufacturing and Sales Capabilities

6.3.2 Targeting Expansion Oversees

6.3.3 Legrand and Germed Key Subsidiaries of EMS

6.4 Medley: Foreign-Owned Generics Leader Maintains 8% Market Share in 2012

6.5 Hypermarcas: Diversified Drugstore Chain

6.5.1 Neo Química Genericos: Third-Ranked in Generics Segment

6.5.2 Other Key Hypermarcas Subsidiaries Include Brainfarma

6.5.3 Hypermarcas Performance in 2012

6.6 Aché: The Major Acquisition Target in Brazil

6.6.1 Cardiovascular Drugs the Main Focus

6.6.2 Ache: Possible M&A?

6.6.3 A Large Domestic Merger an Alternative Possibility?

6.7 Laboratorios Eurofarma: Diversified Leader with Hospital, Generic and Veterinary Business

Units

6.7.1 Vigorous Latin American Acquisitions Policy

6.7.2 Strong Presence in Cancer Treatment

6.8 Laboratorio Teuto Brasileiro: Largest Pharmaceutical Complex in Latin America

6.8.1 Melcon Partnership and Other Growth Strategies for Teuto

6. Domestic Companies in the Brazilian Market, 2014-2024

Page 6: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents 6.9 Biolab-Sanus Farma: 100+ Products, Four Exclusive

6.9.1 Collaborations with Emcure and Merz

6.10 Laboratório Cristália: R&D Leader

6.10.1 Leader in API Manufacturing

6.10.2 Involved in Nearly Half of All PDP Arrangements

6.11 Libbs Farmacêutica: Key Player in Cancer Treatment

6.11.1 Working on a Biosimilar – Opening New Possibilities

6.12 Uniao Quimica Farmaceutica Nacional: Expanding in Minas Gerais

6.13 Other Domestic Players

6.14 The Major Biosimilar Collaborations

6.14.1 BioNovis: Aiming at Commercialisation by 2015

6.14.2 Orygem Biotecnologia

6.15 Other Potential Sources of Innovation

6.15.1 Fundação Oswaldo Cruz: At the Heart of PDP

6.15.2 ANVISA Reform of Brazilian Patent System

7.1 M&A Propels Sanofi into First Position

7.2 Multinational Investment in the Market Continues to Grow

7.3 Sanofi: Medley Purchase Makes French Giant the Outright Leader

7.3.1 Genzyme and Consumer Health the Main Growth Drivers

7.3.2 Generics Sales Stall in 2012

7.3.3 Inventory and 2013 Results

7.4 Novartis: Brazil Now Sixth-Largest Market

7.4.1 Sandoz Sales Grow by 29% in 2012

7.4.2 Pricing and Reimbursement Solutions to Bring Original Drugs to Brazil

7.4.3 Co-operating on Technology Transfer and Other Ideas

7.5 Roche: Double-Digit Brazilian Growth in 2012

7.5.1 Positioned to Tap the Oncology Opportunity

7. Multinational Companies in the Brazilian Market, 2014-2024

Page 7: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents 7.5.2 Herceptin, Pricing and Reimbursement

7.6 Merck & Co. – Long-Standing Presence in the Brazilian Market

7.6.1 Gardasil Added to SUS in 2013

7.6.2 ExcelRX JV to Increase Merck’s Standing in Brazil

7.7 Pfizer: Targeting Emerging Market Growth via M&A

7.7.1 Portfolio Ranges from Orphan Biologics to Multivitamins

7.7.2 How Will a Pfizer Break-Up Affect Emerging Market Plans?

7.8 Bayer: Brazil Fifth-Largest Market for Diversified Conglomerate

7.8.1 Consumer Health a Major Focus in Brazil

7.9 AstraZeneca: Struggling with Patent Expiries in Brazil

7.9.1 Possible Future Growth Drivers Include Diabetes

7.10 Boehringer Ingelheim: Pain, Cardiovascular and Respiratory Drugs Bolster Strong National

Portfolio

7.10.1 Technology Transfer Deal for Sifrol

7.11 Takeda: Entering the Top 10 with Multigrip OTC Acquisition

7.11.1 Nycomed Generics and Original Products Also Key to Strategy

7.12 Merck Serono: Over 6% Consumer Health Growth Forecast

7.13 Other Big-Pharma Competitors

7.13.1 Johnson & Johnson: Focusing on Consumer Health and Commodities

7.13.2 GlaxoSmithKline: Vaccines Technology Transfer Opportunities

7.13.3 Abbvie: Humira to Face Biosimilar Challenge in Brazil?

7.13.3.1 Abbott: Generics and Diagnostics-Led Growth Strategy

7.13.4 Eli Lilly: Patent Expiries Hit Emerging Market Revenues.

7.13.5 Bristol-Myers Squibb: Divesting its Brazilian OTC Portfolio Rights

7.13.6 Baxter: Entering Brazilian Haemophilia Market via Tech Transfer

7.13.7 Amgen Signals Brazilian Intent with Bergamo Acquisition

7.13.8 Other Top Biotechs Enter Brazil

7.13.9 Other Top Japanese Companies Trail Behind Takeda in Brazil

7.14 Will Multinational Generics Leaders Compete in Brazil?

7.14.1 Teva Pharmaceutical Industries: Generics Giant Targets Brazil

Page 8: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents 7.14.2 Mylan: Agile Acquisition Boosts Latin American Strategy

7.14.3 Actavis: Newly-Merged Player to Challenge in Brazil

7.14.4 Ranbaxy Hands Over to Daiichi, but Other Indian Companies Still in the Hunt in Brazil

7.14.5 Glenmark, Strides and Biocon Looking to Enter Brazil

7.14.6 Valeant: Aggressive M&A Drive Into the Market

7.15 Brazil as Research Destination

7.16 Other Multinational Business in Brazil

8.1 A Crucial Market for the Pharmaceutical Industry?

8.2 Governmental Regulation Remains an Issue

8.3 Room to Expand in Therapeutic Areas and Geographical Regions

8.4 IP Protection: Doubts, Red Tape and Counterfeiting Remain Issues

8.5 Large and Ageing Population Eager to Buy Medicines

8.6 Improved Biotechnology and Digital Among Government’s Goals

8.7 Can Economic Growth Keep Pace With Healthcare Costs?

8.8 Political Environment the Decisive Influence on the Market

9.1 Brazil Likely to Outperform Most Other Top 10 Pharma Markets

9.2 Generics to be the Fastest-Growing Segment

9.3 Technology Transfer Crucial to Patented Drugs Market

9.4 Generics and Patented Products: Opportunities for Multinationals

9.5 Anti-cancer Drugs: Biggest Therapeutic and Commercial Opportunity

9.6 Concluding Remarks

8. Qualitative Analysis of the Brazilian Market, 2014-2024

9. Conclusions from the Research and Analysis

Page 9: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents

Table 1.1 Currency Exchange Rates

Table 2.1 Brazilian Pharmaceutical Market: Revenues ($m), AGR (%), CAGR (%), 2012-2017

Table 2.2 Brazilian Pharmaceutical Market: Revenues ($m), AGR (%), CAGR (%), 2018-2024

Table 2.3 Product Mix Breakdown: Revenues ($m), Market Share (%), 2012

Table 2.4 Therapeutic Area Breakdown: Revenues ($m), Market Share (%), 2012

Table 2.5 Leading Companies in the Brazilian Pharma Market: Revenues ($m), Market Shares

(%), 2012

Table 2.6 Leading National Markets Worldwide: Revenues ($m), Market Shares (%), 2012

Table 2.7 Leading National Markets in Latin America: Revenues ($m), Market Shares (%), 2012

Table 2.8 Leading National ‘Pharmerging’ Markets: Revenues ($m), Market Shares (%), 2012

Table 3.1 Members of FenaSaúde, 2013

Table 4.1 Brazilian Pharma Market Breakdown by Product Type: Revenues ($m), AGR (%),

CAGR (%), Market Share (%), 2012-2017

Table 4.2 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), Market

Shares (%), 2017

Table 4.3 Brazilian Market Breakdown by Product Type: Revenues ($m), AGR (%), CAGR (%),

Market Shares (%) 2018-2024

Table 4.4 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), Market

Shares (%), 2024

Table 4.5 Selected Technology Transfer Agreements in Brazil 1985-2013

Table 4.6 Patented Pharmaceuticals: Revenues ($m), AGR (%), CAGR (%), Market Share (%),

2012-2017

Table 4.7 Patented Pharmaceuticals: Revenues ($m), AGR (%), CAGR (%), 2018-2024

Table 4.8 Generic Pharmaceuticals: Revenues ($m), AGR (%), CAGR (%), Market Share (%),

2012-2017

Table 4.9 Generic Pharmaceuticals: Revenues ($m), AGR (%), CAGR (%), Market Share (%),

2018-2024

List of Tables

Page 10: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents Table 4.10 OTC Pharmaceuticals: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-

2017

Table 4.11 OTC Pharmaceuticals: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-

2024

Table 5.1 Brazilian Market Breakdown by Therapeutic Area: Revenues ($m), AGR (%), CAGR

(%), Market Shares (%) 2012-2017

Table 5.2 Therapeutic Area Breakdown: Revenues ($m), Market Share (%), 2017

Table 5.3 Brazilian Market Breakdown by Therapeutic Area: Revenues ($m), AGR (%), CAGR

(%), Market Shares (%) 2018-2024

Table 5.4 Therapeutic Area Breakdown: Revenues ($m), Market Shares (%), 2024

Table 5.5 CNS Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Shares (%), 2012-

2017

Table 5.6 CNS Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-

2024

Table 5.7 Cardiovascular Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share

(%), 2012-2017

Table 5.8 Cardiovascular Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share

(%), 2018-2024

Table 5.9 Alimentary/Metabolic Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market

Share (%), 2012-2017

Table 5.10 Alimentary/Metabolic Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market

Share (%), 2018-2024

Table 5.11 Oncology Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share (%),

2012-2017

Table 5.12 Oncology Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share (%),

2018-2024

Table 5.13Infectious Disease Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market

Share (%), 2012-2017

Table 5.14 Infectious Disease Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market

Share (%), 2018-2024

Page 11: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents Table 6.1 Leading Domestic Companies in the Brazilian Market: Revenues ($m), Market Shares

(%), 2012

Table 6.2 EMS: Overview, 2013

Table 6.3 Medley: Overview, 2013

Table 6.4 Hypermarcas: Overview, 2013

Table 6.5 Aché: Overview, 2013

Table 6.6 Eurofarma: Overview, 2013

Table 6.7 Teuto: Overview, 2013

Table 6.8 Biolab Sanus: Overview, 2013

Table 6.9 Cristália: Overview, 2013

Table 6.10 Libbs: Overview, 2013

Table 6.11 Uniao Quimica: Overview, 2013

Table 7.1 Leading Multinational Companies in the Brazilian Market: Revenues ($m), Market

Shares (%), 2012

Table 7.2 Selected Multinational M&A Transactions in Brazilian Market, 2009-2012

Table 7.3 Sanofi: Overview, 2013

Table 7.4 Novartis: Overview, 2013

Table 7.5 Roche: Overview, 2013

Table 7.6 Merck: Overview, 2013

Table 7.7 Pfizer: Overview, 2013

Table 7.8 Bayer: Overview, 2013

Table 7.9 AstraZeneca: Overview, 2013

Table 7.10 Boehringer Ingelheim: Overview, 2013

Table 7.11 Takeda: Overview, 2013

Table 7.12 Merck Serono: Overview, 2013

Table 8.1 Brazilian Pharmaceutical Market: Strengths and Weaknesses, 2013

Table 8.2 Brazilian Pharmaceutical Market: Opportunities and Threats, 2013

Table 8.3 Brazilian Pharmaceutical Market: STEP Analysis, 2013-2024

Page 12: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents

Figure 2.1 Brazilian Pharmaceutical Market: Revenues ($m), 2012-2024

Figure 2.2 Demographic Breakdown of Brazilian Population by Age, 2013

Figure 2.3 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), Market

Shares (%), 2012

Figure 2.4 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), Market

Shares (%), 2012

Figure 2.5 Leading Companies in the Brazilian Market: Revenues ($m), Market Shares (%), 2012

Figure 2.6 Leading National Markets Worldwide: Revenues ($m), Market Shares (%), 2012

Figure 2.7 Leading National Markets in Latin America: Revenues ($m), Market Shares (%), 2012

Figure 2.8 Leading National ‘Pharmerging’ Markets: Revenues ($m), 2012

Figure 2.9 BRIC National Markets: Revenues ($m), 2012

Figure 3.1 Public/Private Balance in Healthcare Provision, 2008

Figure 3.2 CMED-Mandated Maximum Drug Price Rises, 2009-2013

Figure 3.3 Distribution (%) of Revenues Among Brazilian Regions, 2012

Figure 4.1 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), Market

Shares (%), 2017

Figure 4.2 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), Market

Shares (%), 2024

Figure 4.3 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), 2012-2024

Figure 4.4 Brazilian Pharmaceutical Market Product Mix Breakdown: Revenues ($m), 2012,

2017, 2024

Figure 4.5 Biologics in the Brazilian Market: Product Mix Breakdown: Revenues ($m) and Shares

(%), 2012

Figure 4.6 Biologics in the Brazilian Market: Product Mix Breakdown: Revenues ($m), 2012,

2017 and 2024

Figure 4.7 Drivers and Restraints for Prescription Pharmaceuticals, 2013

Figure 4.8 Patented Pharmaceuticals: Revenues ($m), 2012-2024

Figure 4.9 Drivers and Restraints for Prescription Pharmaceuticals, 2013

List of Figures

Page 13: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents Figure 4.10 Generic Pharmaceuticals: Revenues ($m), 2012-2024

Figure 4.11 Drivers and Restraints for Generic Pharmaceuticals, 2013

Figure 4.12 OTC Pharmaceuticals: Revenues ($m), 2012-2024

Figure 5.1 Therapeutic Area Breakdown: Revenues ($m), Market Shares (%), 2017

Figure 5.2 Therapeutic Area Breakdown: Revenues ($m), Market Shares (%), 2024

Figure 5.3 Therapeutic Area Breakdown: Revenues ($m), 2012-2024

Figure 5.4 Therapeutic Area Breakdown: Revenues ($m), 2012, 2017, 2024

Figure 5.5 Drivers and Restraints for CNS Therapeutic Area, 2013

Figure 5.6 CNS Therapeutic Area: Revenues ($m), 2012-2024

Figure 5.7 Drivers and Restraints for Cardiovascular Therapeutic Area, 2013

Figure 5.8 Cardiovascular Therapeutic Area: Revenues ($m), 2012-2024

Figure 5.9 Drivers and Restraints for Alimentary/Metabolic Therapeutic Area, 2013

Figure 5.10 Alimentary/Metabolic Therapeutic Area: Revenues ($m), 2012-2024

Figure 5.11 Drivers and Restraints for Oncology Therapeutic Area, 2013

Figure 5.12 Oncology Therapeutic Area: Revenues ($m), 2012-2024

Figure 5.13 Drivers and Restraints for Infectious Disease Therapeutic Area, 2013

Figure 5.14 Infectious Disease Therapeutic Area: Revenues ($m), 2012-2024

Figure 6.1 Leading Domestic Companies in the Brazilian Market: Revenues ($m), Market Shares

(%), 2012

Table 7.1 Leading Multinational Pharma Companies in the Brazilian Market: Revenues ($m),

Market Shares (%), 2012

Figure 9.1 Brazilian Pharmaceutical Market: Revenues ($m), 2012-2017

Figure 9.2 Brazilian Pharmaceutical Market: Revenues ($m), 2018-2024

Figure 9.3 Product Mix: Revenues ($m), 2012-2017

Figure 9.4 Product Mix: Revenues ($m), 2018-2024

Figure 9.5 Top 10 Companies in the Brazilian Pharma Market, 2012

Figure 9.6 Therapeutic Areas: Revenues ($m) in Brazil, 2012-2017

Figure 9.7 Therapeutic Areas: Revenues ($m) in Brazil, 2018-2024

Page 14: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents

Abbott Laboratories

Abbott Laboratories (including Abbvie)

Achê Laboratórios Farmacêuticos

Actavis

Agência Nacional de Saude Suplementar

Agência Nacional de Vigilância Sanitária (ANVISA)

Agila Specialties

AlfaRio

Alliance Boots

Allianz Health

AMB (Brazilian Medical Association)

American Diabetes Association

American Varian Medical Systems

Amgen

Amil Participações

Antaris Consulting

Arena Pharmaceuticals

Arseus

Associação Brasileira da Indústria de Medicamentos Isentos de Prescrição (ABIMIP)

Associação Brasileira das Redes de Farmácias e Drogarias (ABRAFARMA)

Associação Brasileira de Reabilitação de Coluna

Associacao da Industria Farmaceutica de Pesquisa (InterFarma)

Associação Nacional de Assistencia ao Diabetico (ANAD)

Astellas

AstraZeneca

Athos Pharma

Axis Biotec

Baxter

Bayer

Companies and Other Organisations Mentioned in Report

Page 15: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents BD

Biocon

Biogen Idec

Biolab Emcure

Biolab-Sanus Farma

Biomm

Bionovis

Biosidus

Biovail Corporation

Boehringer Ingelheim

Boiron

Bradesco Saúde

Brainfarma Industria e Farmaceutica

Brasil Pharma

Brazilian Development Bank (BNDES)

Bristol-Myers Squibb

BTG Pactual

Bunker Industria Farmaceutica

Caixa Seguros

Câmara de Regulação do Mercado de Medicamentos (CMED)

Cannes RJ Participacoes

Castro Marques Group

Celesio

Chemo

Claris Lifesciences

CMED

Comissão Nacional de Incorporação de Tecnologia (CONITEC)

Comitê Técnico Assessor de Imunizações (CTAI)

Conselho Administrativo de Defesa Econômica

Corporacion Infarmasa

Page 16: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents CPhI Worldwide

CVS Pharmacy

Daiichi Sankyo

Datamatrix

Delta Instituto Terapeutico

Dimed

Disaq Pharmaceuticals

DM Industria Farmaceutica

Dong-A

DPSP

Drogarias Tamoio

Eisai

Eli Lilly

Emcure

EMS

Eurofarma

Everis

Excel RX

FarmaBrasil group

Farmácia Popular

Farmadacta Informatica

Farmais

Far-Manguinhos

Farmindustria

FDA

Federação Nacional de Saúde Suplementar

Federal Council of Medicine (CFM)

Fiocruz

Food and Drug Administration (US FDA)

Forest Laboratories

Page 17: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents GE

Genfar

Genzyme

Germed Pharma

Gilead Sciences

GlaxoSmithKline (GSK)

Glenmark

Golden Cross Assistance

Grünenthal

Grupo Bradesco

Grupo Cimed

Guararapes

Health Canada

Hebron

Hemobrás

Hospital das Clínicas

Hospital Israelita Albert Einstein

Hospital Santa Catarina

Hypermarcas

IMA Laboratories

Indian Council of Medical Research

Infectious Disease Research Institute (IDRI)

Institut Pasteur

Instituto Butantan

Instituto de Estudos de Saúde Suplementar (IESS)

Interagile Propaganda e Promocoes

Intermédica

Itauseg Health

Johnson & Johnson (J&J)

Kenya Medical Research Institute

Page 18: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents Laboratorio Cristália

Laboratório Daudt Oliveira

Laboratório Farmaceutico do Estado de Pernambuco (LAFEPE)

Laboratorio Quimico Farmaceutico Bergamo

Laboratorio Teuto Brasileiro

Laboratorios Gautier

Laboratórios Kendrick

Laboratórios Klinger Do Brasil

Laramara

Legrand

Libbs Farmacêutica

Locafarma Solucoes de Transportes e Logistica

Luper Indústria Farmacêutica

Mais Econômica

Mantecorp Industria Quimica e Farmaceutica

Maritima Seguros

Mayne Pharma

Médecins sans Frontières

Medley

Meizler Biopharma

Melcon

Merck & Co.

Merck Serono

Merz Pharma

Metlife Dental Plans

Minas Gerais State Department of Health

Ministério da Saúde (Ministry of Health, Brazil)

moksha8

Multilab Industria e Comercio de Produtos Farmaceuticos

Mylan

Page 19: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents Nature's Plus Farmaceutica

Neo Química

Neuberger Machines

Novartis

Novo Nordisk

Nycomed

Odontoprev Omint Health Services

Oncoprod

Optimer Pharmaceuticals

Orygen Biotecnologia

Oswaldo Cruz Foundation

Otsuka

Pan American Health Organization

Panarello

Panpharma

Pasteur Institute

Pele Nova

Penha

Pfizer

Pharmaceutical Product Development, LLC (PPD)

PharmaPraxis

Porto Seguro

Probiomed

Probiotica

Procter & Gamble

Profarma

Pró-Genéricos

Promovendas Representacoes

Protalix BioTherapeutics

Quesada Farmaceutica

Page 20: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents Quintiles

RaiaDrogasil

Ranbaxy

Reckitt Benckiser

Regional Council of Medicine, State of São Paulo

Roche

Rosário

Sabin Vaccine Institute

Sandoz

Sanofi

Sant’Ana

Santa Cruz

Shasun Pharma

Siemens

Sincamesp

Sinclair IS Pharma

Sindusfarma

Sistema Único de Saude (SUS)

Strides Arcolab

SulAmérica

Sun

Supera Farma Laboratorios

Takeda

Telefônica Digital

Tempo Participações

Teva Pharmaceutical industries

TKS Farmaceutica

Torrent

Toshiba

UCB

Page 21: Brazilian pharmaceutical market 2014

www.visiongain.com

Contents UERJ

UFMG

UFRJ

Uniao Quimica

UNICAMP

UNIFESP

Unimed Seguros

UnitedHealth

University of São Paulo

Valeant

Varian Medical Systems

Volta

Walgreens

Watson Pharmaceuticals (now Actavis)

Wheaton Brazil

Wockhardt

World Health Organization (WHO)

Zydus Cadila

Page 22: Brazilian pharmaceutical market 2014

Page 79

www.visiongain.com

Brazilian Pharmaceutical Market 2014-2024

5.4.4 The Heart Disease Opportunity Over the Next 10 Years Figure 5.7 indicates drivers and restraints for the cardiovascular therapeutic area in Brazil.

The main driver for the cardiovascular therapeutic area lies simply in the vast levels of medical

need in the country. If, as some estimates suggest, almost 60 million Brazilians suffer from some

form of cardiovascular condition (principally hypertension), then this is a major commercial

opportunity. The difficulty comes in the fact that the majority of cardiovascular treatments are

preventative and depend on good information for personal health management on the part of the

population. Since many of the most important cardiovascular drugs have also lost patent

protection, the growth of the generics segment will be a necessary factor in the continued

expansion of this therapeutic area. For example, generic simvastatin is a market leader, and other

generic statins and other molecules will become key drivers in the near-term. The widespread use

of OTC cardiovascular treatments may be a restraint on the market inasmuch as it restricts use of

the major prescription drugs.

5.4.5 Market Forecast for Cardiovascular Therapeutic Area 2014-2024 The cardiovascular therapeutic field will expand with a five-year CAGR of 6% to achieve 2017

revenues of $6211m. Over this period, its market share will decline from 17% to 15%. See Table

5.7. By 2024, revenues for the therapeutic area will reach $8790m, with a CAGR of 6% across the

forecast period as a whole. See Table 5.7, Table 5.8 and Figure 5.8.

Drivers

Restraints

Very high prevalence of cardiovascular disease, with strokes and heart attacks likely to rise

sharply over the forecast period

Government access to hypertension treatments allows major take-up for this leading unmet

medical need

Significant interest from companies at home and abroad

Patent expiries for statin drugs take away a key revenue driver for the therapeutic area

Awareness of hypertension remains low among

the population

Heavy OTC use may restrict opportunities for more expensive Rx drugs

Figure 5.7 Drivers and Restraints for the Cardiovascular Therapeutic Area, 2013

Source: visiongain 2013

Page 23: Brazilian pharmaceutical market 2014

Page 80

www.visiongain.com

Brazilian Pharmaceutical Market 2014-2024

5.5 Alimentary/Metabolic Diseases: Affecting More Than a Third of

Brazilians Prevalence of alimentary/metabolic conditions in Brazil is high, with over a quarter of the

population suffering from gastrointestinal conditions including gastroesophageal reflux disease and

inflammatory bowel conditions. Two of the top-selling generic drugs in the country in H1 2013 were

pantoprazole and omeprazole, the proton pump inhibitors for reducing stomach acid, which jointly

accrued over $90m in revenues for that six-month period. Diabetes is also a major issue in

Brazilian healthcare, with WHO estimates indicating that prevalence will increase by two-thirds

between 2010 and 2030. Since 2006, diabetes treatments are now distributed free via the

Farmácia Popular channel discussed previously.

Table 5.7 Cardiovascular Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2012-2017

2012 2013 2014 2015 2016 2017

Revenues ($m) 4544 4865 5237 5566 5914 6211

AGR (%) 7 8 6 6 5

CAGR (%, 2012-2017) 6

Market share (%) 17 16 16 16 16 15

Source: visiongain 2013

Table 5.8 Cardiovascular Therapeutic Area: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2018-2024

2018 2019 2020 2021 2022 2023 2024

Revenues ($m) 6570 6931 7280 7561 7975 8366 8790

AGR (%) 6 5 5 4 5 5 5

CAGR (%, 2018-2024) 5

CAGR (%, 2012-2024) 6

Market share (%) 15 14 14 14 14 13 13

Source: visiongain 2013